According to The Insight Partners market research study titled Prenatal and Newborn Genetic Testing Market – Global Analysis and Forecasts by Product, Disease Indication and End User. The Global Prenatal and Newborn Genetic Testing Market is expected to reach US$ 11,204.7 Mn in 2027 from US$ 4,034.4 in 2018. The market is estimated to grow with a CAGR of 12.2% from 2019-2027. The report highlights the trends prevalent in the global prenatal and newborn genetic testing market and the factors driving the market along with those that act as deterrents to its growth.
Download Sample PDF Prenatal and Newborn Genetic Testing Report Copy at: https://www.theinsightpartners.com/sample/TIPBT00002550/
Market Insights
High Prevalence of Genetic Diseases in Infants
Several types of genetic diseases affect the fetuses in the womb. The way in which these genetic diseases are inherited helps to determine the risk that they pose on pregnancy as well as the risk of its recurrence. The risk of having genetic diseases in babies is high in cases where the parents have another child with a genetic disease, family history of a genetic disorder, or if either of a parent has a chromosomal abnormality. There is a significant prevalence of genetic diseases among infants. Moreover, these diseases are also responsible for infant mortality across the globe. For instance, according to the World Health Organization 2016, an estimated 7.9 million infants across the world are born with genetic defects. Moreover, according to the Centers for Disease Control and Prevention (CDC), birth defects affects every 1 in 33 babies born in the US. On the other hand, chromosomal abnormalities such as Down syndrome affects 1 in 691 babies born in the US, as per the CDC’s data in 2017.
Thus, the high prevalence of genetic diseases among infants account for the increasing demands for prenatal and newborn genetic tests, thereby contributing to the growth of the market.
Emerging Markets in Developing Countries
The emerging markets in the developing countries in the Asia Pacific region are creating better opportunities for the major market players to expand their business. This is a major reason for the market growth in the forecast period. Most of the major players focus on emerging markets such as India, China, and others. As they have a large number of population and technological advancements in these countries also favor the growth of the market.
Furthermore, the growing healthcare sector in this region is likely to enhance the growth opportunities for the prenatal and newborn genetic testing market. For instance, the increasing number of corporate hospitals like Apollo group, Max, Fortis, and others in India is likely increasing professionalism as well as lead to the emergence of the latest medical technology. Max Healthcare offers the prenatal test in India in order to identify as well as prevent the permanent disability in the newborn.
Thus, growing population in emerging countries and advanced healthcare sector in the region is likely to boost the market and is expected to provide significant growth opportunities to the players operating in the market during the forecast period.
Product Insights
Based on product, the global prenatal and newborn genetic testing market was segmented into screening and diagnostics. In 2018, the screening segment held the largest market share of 59.1% of the prenatal and newborn genetic testing market, by product. Moreover, the same segment is also expected to witness the highest CAGR over the coming years owing to the factors such as increasing number of pregnant females adopting prenatal screening, increased mandatory regulations for newborn screening tests and others. Moreover, screens are the first line tests that pregnant women and newborn undergoes that also adds up to the major share of the market and its dominance in the global market.
Strategic Insights
Product launches, partnerships, and acquisitions were observed as the most adopted strategy in global prenatal and newborn genetic testing market industry. For instance, in June 2019, Illumina introduced VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). The comprehensive automated solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth defects and adverse pregnancy outcomes than the standard NIPT menu. Moreover, in April 2019, Abbott acquired Alere, a diagnostic device and service provider for $5.3 billion. Alere offers products like Alere Actim PROM, a test which used to diagnose the rupture of fetal membranes in pregnant women. Thus enhancing Abbott’s prenatal product portfolio.
On basis of product, the global prenatal and newborn genetic testing market was segmented into screening and diagnostics. In 2018, the screening segment held the largest market share of 59.1% of the prenatal and newborn genetic testing market, by product. Moreover, the same segment is also expected to witness the highest CAGR over the coming years owing to the factors such as increasing number of pregnant females adopting prenatal screening, increased mandatory regulations for newborn screening tests and others. Moreover, screens are the first line tests that pregnant and newborn undergo that also adds up to the major share of the market and its dominance in the global market.
Key factors driving the growth of the market are a high prevalence of genetic diseases in infants, support from government to promote prenatal and newborn genetic test, and increase the birth rate in various countries across the globe. On the other hand, emerging market in developing countries is likely to offer growth opportunities that are operating in the global prenatal and newborn genetic testing market.
Some of the prominent players operating in prenatal and newborn genetic testing market are, Abbott, Quest Diagnostics Incorporated, Ravgen, Bio-Rad Laboratories, Inc., Illumina, Inc., F. Hoffmann La-Roche Ltd., Qiagen, Berry Gene, PerkinElmer, Inc., Natera, Inc., and Laboratory Corporation of America Holdings (Sequenom) among others. The market players are focused on bringing new and innovative products and services through various inorganic strategies such as acquisitions and mergers to sustain their position in the market. For instance, in September 2016, Laboratory Corporation of America (LabCorp) completed the acquisition of Sequenom, a genetic diagnostic company that offers diagnostic testing applications as well as genetic analysis products. LabCorp aims to establish a footprint into the prenatal and genetic diagnostic testing market through this acquisition.
Global Prenatal and Newborn Genetic Testing Market, By Regions, 2018 (%)
The report segments the global prenatal and newborn genetic testing Market as follows:
Global Prenatal and Newborn Genetic Testing Market – By Product
Global Prenatal and Newborn Genetic Testing Market – By Disease Indication
Global Prenatal and Newborn Genetic Testing Market – By End User
Global Prenatal and Newborn Genetic Testing Market – By Geography